Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

January 5, 2018: By Jon Swedien

Legal issuePershing Square and Valeant Pharmaceuticals have agreed to pay $290 million to settle a lawsuit accusing the companies of insider trading before making a bid to buy Allergan in 2014, both companies announced in late December 2017.

However, a federal judge still must approve the deal.

US District Judge David Carter has questioned the proposed settlement, saying he has “substantial questions whether the settlement amount is reasonable and fair.” Carter set a hearing for Jan. 16 for attorneys from both corporations and the plaintiffs to explain their positions on the deal, according to media reports.

Both companies have said they are not guilty of the insider trading charges brought on behalf of investors who sold Allergan shares in the two months before the companies’ unsolicited $51 billion bid for Allergan.

Pershing Square CEO Bill Ackman and Valeant CEO Joseph Papa—who took the position in 2016 after the alleged insider trading—both said the settlement was in their companies’ best interest because it would allow them to move on.

Under the proposed settlement, Pershing Square will pay about two-thirds of the settlement, or $193.75 million. Valeant will pay about a third, or $96.25 million.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023